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The functionalization of natural polymer-coated
gold nanoparticles to carry bFGF to promote
tissue regeneration†
Helena Ferreira, *ab Albino Martins, ab Marta L. Alves da Silva, ab
Sara Amorim, ab Susana Faria, c Ricardo A. Pires, ab Rui L. Reis ab and
Nuno M. Neves *ab
Gold nanoparticles (AuNPs) enable the treatment and real-time monitoring of several diseases, providing
an exciting and advantageous nanomedicine strategy. These NPs have therefore been adequately
functionalized to enable them to carry growth factors (GF), namely basic fibroblastic (bF) GF, which play
an essential role in diﬀerent and important cellular processes including cellular proliferation, survival,
migration and diﬀerentiation. The AuNPs were coated with natural polymers, chitosan and heparin, to
enhance their physicochemical properties such as suspension stability. The polyelectrolyte coating was
monitored using a quartz crystal microbalance with dissipation, size and zeta-potential analysis. The
natural polymer-coated AuNPs have a spherical shape and a positive surface charge due to chitosan
amino groups, enabling their biofunctionalization with monoclonal antibodies to target specific
biomolecules. Additionally, cellular assays with the chondrocyte cell line ATDC5 show that the NPs are
cytocompatible at relevant concentrations. As a proof of concept of their potential application in tissue
regeneration, the natural polymer-coated AuNPs were further functionalized with an antibody to
selectively bind the desired GF. The bFGF concentration reached in the NPs without compromising the
cytocompatibility demonstrates the potential of this carrier for tissue regeneration.
1. Introduction
Nanoparticles (NPs) are successfully used in both therapeutic
and imaging applications. Currently, there are a significant
number of NP-based formulations in clinical use, approved by
the Food and Drug Administration (FDA) and/or by the European
Medicines Agency (EMA).1,2 Many other NP formulations can
follow the same trend, due to the promising preclinical results
and the growing number of human clinical trials.1,2 However, in
recent years, significant eﬀorts have beenmade towards obtaining
both therapeutic and imaging capabilities in a single NP platform.
This combination within a single formulation has led to the
research field of theranostics.3 Theranostic NPs present unique
capabilities, namely non-invasive administration and real-time
monitoring of the therapeutic eﬀect or disease evolution, evalua-
tion of the therapeutic agents pharmacokinetic and target site
accumulation, adjustment of the dose and administration
frequency during the treatment, the ability to track and quantify
drug release, and can result in synergistic therapeutic eﬀects of
the medicine and the imaging agent (e.g., by light, thermal and
photothermal therapies).3–6 Theranostic formulations therefore
have the potential to translate the current ‘‘one-size-fits-all’’
therapy into truly precision medicine.
Among the numerous imaging agents that have been proposed,
gold (Au)NPs have been of particular interest due to their unique
properties such as biocompatibility, chemical stability and inert-
ness, easy preparation in a variety of sizes and shapes, eﬀortless
surface modification and tunable optical properties.7–10 Moreover,
they can be detected by a variety of imaging techniques such as
X-ray attenuation,11 multiwavelength photoacoustic imaging,12
surface-enhanced Raman scattering,13 near-infrared irradiation14
and computed tomographic imaging.15 In therapeutics, AuNPs can
lead to photodynamic7,16–18 or photothermal19–22 damage of micro-
organisms and cancer cells, and they can also be the therapeutic
agent themselves.23–25 Additionally, AuNPs can serve as a carrier for
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therapeutic agents, namely peptides,26 proteins,27 drugs28 and
nucleic acids.29,30 As a diagnostic tool, these particles can be
used in the visualization and bioimaging of several chemical and
biological agents, in analytical diagnostic methods (e.g. immuno-
chromatographic tests) and as biosensors (e.g. for diagnosis of
infections or detection of toxins in food or biological fluids).7,31
AuNPs are therefore a very useful tool to use in diverse clinical
conditions. Indeed, despite the huge diversity of metal NPs,
AuNPs are among the most used in biological applications.32
AuNPs are commonly engineered with a polymeric coating
to improve their physicochemical properties. Several natural or
synthetic biocompatible polymers have been used to avoid the
aggregation of AuNPs, to improve their payloads, to impart
biocompatibility, to develop external or internal stimuli trig-
gered systems, and to increase the residence time in the
circulation,33–36 avoiding early clearance by the reticulo-
endothelial system. The polymeric coating of AuNPs can be
carried out by several methods.33,34 The layer-by-layer (LbL)
assembly is a simple, reliable, easy, robust, cost-effective and
versatile bottom-up technology that has been widely applied
to produce a multitude of multi-layered-architectures with
nanometer precision and exhibiting different functionalities
to target the ultimate and desired application.37–40 Moreover,
LbL assembly allows the coating of any kind of substrate (e.g.
3-dimensional substrates) of almost any surface chemistry and
under environmental friendly experimental conditions, which
is extremely important when biomolecules are used.41 Conse-
quently, this promising approach surpasses several limitations
present in other currently used thin film deposition methods
such as dip-coating.41 Therefore, in this work, the coating of the
AuNPs surface was performed by the LbL methodology using
two natural biodegradable polymers, namely, chitosan and
heparin. Chitosan is a polycation that is already used in the
preparation of biomedical devices since it presents anti-
bacterial activity,42,43 hemostatic activity and has the ability to
accelerate wound closure and healing.44 On the other hand,
heparin, a strong polyanion that can promote stronger com-
plexation with chitosan, is a widely used anticoagulant and a
highly effective polymer in stabilizing growth factors (GFs) like
the basic fibroblast GF (bFGF or FGF-2).45 Therefore, the
association of biological drugs with a device comprising the
intrinsic properties of these two polymers will allow for protection
and synergistic therapeutic effects; for example, chitosan-coated
AuNPs have antioxidant activity in vivo.46
As a proof of concept, and aiming to validate the ability of
the developed NPs to serve as a nanoplatform to carry a
bioactive factor, the immobilization of a defined antibody that
binds bFGF was investigated. This GF has the ability to interact
with diverse cell types from the vascular, nervous and connec-
tive tissues.47,48 bFGF, is in fact, a potent regulator of cell
proliferation, diﬀerentiation, migration and survival, as well
as angiogenesis and wound repair.48–50 Nevertheless, bFGF, like
other therapeutic agents (such as nucleic acids and peptides),
should be administered using an appropriate carrier that allows
the enhancement of its half-life and ensures the preservation of
its active form.51 Therefore, the in vivo administration of bFGF is
commonly associated with heparin or heparin sulfate to avoid its
physical denaturation and proteolytic degradation.47 Moreover,
bFGF bound to this glycosaminoglycan seems to be more effective
than its uncomplexed analogue.52 Indeed, there are several
studies in the literature that demonstrate the therapeutic
potential of this heparin-binding GF.53–60 bFGF has been the
target of different clinical trials for tissue regeneration, such as
periodontal disease and bone fractures. For example, Trafermin,
the first recombinant human bFGF product, has been used in
clinical practice since June 2001 to treat bed sores and skin
ulcers.61
This work aims to develop a stable biofunctional polymeric-
coated AuNP by the LbL assembly of two natural biodegradable
polymers with opposite charges, i.e. chitosan and heparin,
without the use of synthetic polymers and/or crosslinkers.
The adsorption of several layers, instead of one, provides
several advantages in the resulting NPs, namely improved
stability and robustness as well as a more homogeneous poly-
meric coating along the NPs surface. Indeed, a greater number
of adsorbed layers will increase the inter-layer electrostatic
interactions and consequently, the cohesion and mechanical
stability of the LbL coating, even in vivo.62 The adsorption
process of the natural polymers at the Au surface was firstly
followed by quartz crystal microbalance with dissipation (QCM-D)
and then by particle size and zeta potential measurements.
Nanoparticle tracking analysis (NTA) was also performed to
evaluate the NPs size, as well as atomic force microscopy (AFM)
and transmission electron microscopy (TEM). Besides giving
an indication of the NPs size, the last two characterization
techniques are exceptionally important in the investigation of
their morphology. Cellular assays were performed with a cell
type closely related to the proposed therapeutic indication,
namely the chondrocyte cell line ATDC5, which is excellent
for finding promising formulations to use in cartilage repair.63
Additionally, the local administration of the developed NPs in
the joint cavity will lead primarily to high concentrations in the
vicinity of chondrocytes. Cellular studies were conducted to evaluate
the natural polymer-coated AuNPs cytocompatibility, as well as to
assess cell proliferation and protein synthesis. Fourier transform
infrared spectroscopy (FTIR) and the Ellman’s reagent method64
were used to ensure that chitosan was in the external layer of the
AuNPs coating, leading to the presence of free amino groups that
allow the functionalization of the particles. The antibody anti-bFGF
was linked and afterwards it was performed the binding of bFGF to
the natural polymer-coated AuNPs surface.
2. Experimental
2.1. Materials and reagents
Gold(III) (Au3+) chloride trihydrate, sodium citrate dehydrate,
N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride
(EDC), N-hydroxysuccinimide (NHS), 5,5 0-dithiobis(2-nitro-
benzoic acid) or Ellman’s reagent (DTNB), 2-iminothiolane (2IT),
4-(dimethylamino)pyridine (DMAP), potassium bromide (KBr),
sodium chloride (NaCl), phosphate buﬀered saline (PBS) tablets,
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bovine serum albumin (BSA), heparin (grade I-A; 42 kDa; degree of
sulfation, DS = 1.8–2.4) and nitric acid (HNO3) were purchased
from Sigma-Aldrich. Chitosan (MW = 154 kDa; Mn = 56 kDa) was
acquired from Heppe Medical Chitosan GmbH. Hydrochloric acid
(HCl) and sodium hydroxide (NaOH) were purchased from Fisher
Scientific. Au standard solution of 1000 g L1 (in HCl 20%) for ICP
determinations was obtained from Panreac. The anti-FGF-2/basic
FGF antibody, clone bFM-2 (non-neutralizing antibody), was pur-
chased from Millipore (05-118) and the secondary antibody Alexa
Fluors 488 Rabbit Anti-Mouse IgG was purchased from Life
Technologies. The recombinant human bFGF was acquired from
PeproTech (AF-100-18B). Dulbecco’s modified Eagle’s medium-F12
(DMEM-F12), antibiotic/antimycotic solution (10000 units mL1
penicillin G sodium, 10000 mg mL1 streptomycin sulfate, and
25 mg mL1 amphotericin B), fetal bovine serum (FBS), trypLE
Express and Quant-iTt PicoGreens dsDNA Kit were purchased
from Life Technologies. CellTiter 96 AQueous One Solution kit was
purchased to Promega, whereas Micro BCAt Protein Assay Kit was
purchased from Thermo Scientific. All reagents were used without
any further purification.
2.2. QCM-D measurements
The build-up of a three bilayer system, composed of two layers
of chitosan (polycation) interspersed with one layer of heparin
(polyanion), was followed in situ by a QCM-D (E4 instrument,
Q-Sense), using Au-coated AT-cut quartz crystals (QSX301,
Q-Sense). Polyelectrolyte solutions were freshly prepared at a
concentration of 1 mg mL1 for heparin and 0.5 mg mL1 for
chitosan in 0.15 M NaCl solution (pH E 5). To obtain the
heparin solution, a known amount of heparin was dissolved in
0.15 M NaCl. To prepare the chitosan solution, it was necessary
to use a solution of 1% acetic acid in 0.15 M NaCl. The pH
adjustment of the solutions was performed with HCl or NaOH
solution.
The QCM-D flow chambers were flushed at a flow rate of
50 mL min1 with a 0.15 M NaCl solution until a stable baseline
was obtained. The chitosan solution was added to the chambers
at the same flow rate and was allowed to adsorb for 15 min. After
this first layer adsorption, the sensors were rinsed with the salt
solution to remove loosely bound material, for the same period
of time. The second layer (heparin) was injected into the
chambers and allowed to adsorb for the same period of time,
followed by the rinsing step. These adsorption steps were repeated
until a chitosan–heparin–chitosan coating was obtained.
QCM-D measurements were performed at several harmonics
(n = 3, 5, 7, 9, 11 and 13); however, only the 3rd, 5th and 7th
were considered for further analysis. Thickness calculation was
performed on the Q-Tools software (v 3.0.6.213), using the
Sauerbrey model.
2.3. AuNPs preparation and coating
Citrate-capped AuNPs were prepared using the Turkevich
method.65 Briefly, 0.1 M of sodium citrate was added to reduce
the Au salt (1 mM) previously heated to the boiling temperature.
The mixture was stirred for at least 3 h at room temperature (RT).
After washing the AuNPs with water, they were coated using the
LbL methodology. The addition of the AuNPs to the polymer
solution in 0.15 M NaCl (pH E 5), prepared as previously
mentioned, was placed in an ultrasound bath. The particles were
coated with three natural polymeric shells, which were composed
sequentially of chitosan then heparin then chitosan. The adsorp-
tion of each polymer to the NPs was performed under stirring for
30 min, at RT. Between each adsorption, the suspension was
rinsed with water and then placed in the ultrasound bath to
disrupt the aggregates.
2.4. Size distribution and zeta-potential measurements
Intensity-distribution size was assessed using dynamic light
scattering (DLS) at an angle of 1731 and at a wavelength of
633 nm. Zeta-potential values were obtained by laser Doppler
electrophoresis. DLS determinations were performed with
disposable polystyrene cuvettes. The zeta-potential was mea-
sured using a dip cell. The measurements were performed at
25.0  0.1 1C using a Zetasizer Nano ZS instrument (Malvern
Instruments). The samples were diluted with ultra-pure water,
but the dilution factors were diﬀerent, based on the NPs
suspension being analysed, since they presented diﬀerent
initial concentrations.
2.5. NTA experiments
NTA experiments allowed the determination of the size and
concentration of the NPs suspension, using both light scattering
and Brownian motion. Since the NanoSight NS500 instrument
includes a charge-coupled device camera it was possible to
visualize the NPs under Brownian motion because they scattered
the light of the laser beam. Each video was recorded for 60 s using
the NTA analytical software version 2.3. The analysis was
performed at RT for samples that were diluted at least 50 times
compared to the tested concentrations in the Zetasizer equipment.
2.6. AuNPs morphology
The morphology of AuNPs coated (or not) with natural polymers
was assessed using atomic force microscopy (AFM; Dimension
Icon, BRUKER) and transmission electron microscopy (TEM; Jeol
JEM-1400). AFM analyses (tips Scanasyst Air) were performed
in air using dried (at RT) samples deposited on a glass slide.
For negative staining TEM, 10 mL of samples were mounted on
Formvar/carbon film-coated mesh nickel grids (Electron Micro-
scopy Sciences, Hatfield, PA, USA) and left standing for 2 min.
The excess liquid was removed with filter paper, 10 mL of 1%
uranyl acetate was added to the grids and left standing for 10 s,
after which excess liquid was again removed with filter paper.
Visualization was carried out at 80 kV.
2.7. FTIR analysis
FTIR spectra of KBr pellets of the samples were obtained, at RT
using a Shimadzu-IR Prestige 21 spectrometer, as the average of
32 individual scans. The spectral region was from 4000 to
800 cm1 with a resolution of 2 cm1, with the background
spectra automatically subtracted.
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2.8. Quantification of free amine groups
The amount of amino groups present in the natural polymer-
coated AuNPs was determined using the method described by
Tyllianakis et al.64 and Monteiro et al.66 This method allows the
determination of the number of free amino groups by reacting
these groups with a solution of equal concentrations of 2IT and
DMAP (20 mM) in PBS (0.1 M, pH 8) for 1 h at 37 1C, giving rise
to sulfhydryl groups. After the NPs were washed, they were
added to DTNB (0.1 mM) in PBS (0.1 M, pH 7.27), which, in the
presence of the sulfhydryl groups, was cleaved to 2-nitro-5-
thiobenzoate or TNB. This anion was then reduced to the
yellow compound TNB2 at the considered pH. The reaction
was carried out for 1 h at 37 1C and after that, the absorbance of
the supernatant was determined at 412 nm in a microplate
reader (Synergie HT). Since the stoichiometry is 1 : 1 in both
reactions, the determination of the amount of TNB2, using
its molar absorption coeﬃcient value (14 150 M1 cm1),64
allowed the quantification of the amino groups.
2.9. Biological assays
2.9.1. Cell culture and seeding. ATDC5, a mouse chondro-
cyte teratocarcinoma-derived cell line, was supplied by the
European Collection of Cell Cultures (ECACC; UK). ATDC5 cells
were cultured in DMEM-F12 medium (Life Technologies) sup-
plemented with 10% heat-inactivated FBS and 1% antibiotic/
antimycotic solution. The expansion medium was changed
every two days and ATDC5 cells were cultured at 37 1C with
5% CO2. Confluent chondrocyte cells were detached from the
culture flask using TrypLE Express (Life Technologies), counted
on a hemocytometer and seeded at a density of 50 000 cells per
well in a 24 well plate over tissue culture coverslips. NPs at
diﬀerent concentrations were added to the culture medium
24 h later. Triplicates of each condition were collected 24,
48 and 72 h after NPs incubation to conduct the following
biochemical assays.
2.9.2. Cell morphology. At the predefined time points, the
ATDC5 cells were fixed with 2.5% glutaraldehyde in PBS and
dehydrated with increasing concentrations of ethanol. The cells
were then sputter-coated with a thin layer (9–12 nm) of
Au/palladium (Cressington 208 HR) and analysed using scan-
ning electron microscopy (SEM; NanoSEM, Nova 200). Micro-
graphs were recorded at 5.00 kV with magnifications ranging
from 200 to 10 000.
2.9.3. Cell Viability. The viability of ATDC5 cells was deter-
mined by using the CellTiter 96 AQueous One Solution kit
(Promega). At defined times points, a mixture of culture medium
and MTS reagent (5 : 1 ratio) was added to each well and left to
incubate for 3 h at 37 1C in a humidified 5% CO2 atmosphere.
All investigations were performed in triplicate. Thereafter, the
absorbance of the MTS reaction medium from each sample was
read in triplicate at 490 nm (Synergy HT, Bio-TEK).
2.9.4. DNA quantification. DNA quantification was assessed
using Quant-iTt PicoGreens dsDNA Kit (Life Technologies),
according to the manufacturer’s instructions. The specimens
were collected and 1 mL of sterile distilled water was added and
stored at 80 1C until further analysis. Prior to quantification,
the samples were defrosted and sonicated for 15 min. To inter-
polate the DNA values for each sample, a set of standards was
prepared with concentrations ranging from 0 to 1.5 mg mL1.
The fluorescence of each sample was measured on an opaque
96-well plate using a microplate reader (Synergie HT, Bio-Tek)
and an excitation wavelength of 485/20 nm and an emission
wavelength of 528/20 nm.
2.9.5. Total protein synthesis quantification. Total protein
synthesis quantification was performed using the Micro BCAt
Protein Assay Kit (Thermo Scientific), according to the manu-
facturer’s instructions. A standard curve was prepared using
concentrations ranging from 0 to 200 mg mL1. The absorbance
of each sample was measured at 562 nm using a microplate
reader (Synergie HT, Bio-Tek).
2.10. Anti-bFGF immobilization and its quantification at the
NPs surface
The anti-bFGF antibody was immobilized on the natural
polymer-coated AuNPs after its activation using the optimized
ratio of EDC :NHS (50 mM : 200 mM).67 Before putting the
activated antibody in contact with the natural polymer-coated
AuNPs, it was dialyzed (Micro Float-A-Lyzers, MWCO: 3.5–5 kDa)
to remove the excess EDC :NHS. The natural polymer-coated
AuNPs were incubated overnight at 4 1C with an excess of the
activated anti-bFGF. Subsequently, the functionalized AuNPs
were washed with water and then they were immersed in a
solution of BSA (3%) for 1 h at RT. After blocking nonspecific
sites, the secondary antibody, Alexa Fluors, was added to the NPs
pellet, and after 1 h at RT, the fluorescence intensity of the
supernatant (unbound secondary antibody) was measured in a
microplate reader (Synergy HT, Bio-TEK), setting the excitation
wavelength at 485 nm and the emission wavelength at 530 nm.
2.11. Quantification of bFGF binding by the functionalized
AuNPs
To obtain the natural polymer-coated AuNPs bound to bFGF,
equal amounts of bFGF were added to increasing concentra-
tions of NPs. After overnight incubation at 4 1C, the unbound
GF was quantified using the Quantikines Human FGF basic
ELISA Kit (R&D Systems). The assay was performed according
to the manufacturer’s instructions. After addition of the stop
solution to each well, the absorbance values obtained at 450 nm
were corrected by subtracting the data acquired at 540 nm in a
microplate reader (Synergy HT, Bio-TEK).
2.12. Au quantification by inductively coupled plasma optical
emission spectrometry (ICP-OES)
Au concentration was determined via ICP-OES (JY 2000 2,
HORIBA JOBIN YVON, Inc.), at 242.795 nm, after the dissolution
of the AuNPs with 2.5% of HNO3 and 5% of HCl. All measure-
ments were carried out in triplicate.
2.13. Statistical analysis
Physicochemical characterization data were reported as the
average  standard deviation. Statistical analysis of biological
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assays was conducted by using the IBM SPSS software (version 23;
SPSS Inc.). The Shapiro-Wilk test was applied to test the assump-
tion of normality. p values lower than 0.01 were considered
statistically significant. Non-parametric analysis of the data was
done using the Kruskal–Wallis test, followed by Tukey’s HSD test.
3. Results
3.1. Monitoring of the polymeric layer construction by QCM-D
measurements
The frequency and dissipation signal changes are shown in
Fig. 1A; the shifts are higher for the adsorption of chitosan
(1st and 3rd layers) than for heparin. A similar trend was
observed for the polyelectrolyte layer behaviour concerning
the DD/Df values either in the presence of chitosan or heparin
(Fig. 1B). From the analysis of Fig. 1B, the values of DD/Df were
o0.4  106 (with the exception of the chitosan 1st layer at
n = 7), and therefore the multilayer film can be considered
rigid, and the Sauerbrey model can be used to predict the
thickness of each deposited layer.68 The thickness of the multi-
layer film reached approximately 5.5 nm (Fig. S1, ESI†), with
a larger contribution from the chitosan layers (a total of
approximately 5 nm for the 2 layers) than the heparin layer
(approximately 0.5 nm for 1 layer). The mass of each adsorbed
layer (polymer plus coupled water) was also quantified,
presenting the first and last layers of chitosan E2.41 and
1.05 mg cm2, respectively, and for heparin the value obtained
was E0.15 mg cm2.
3.2. AuNP characterization
The size, polydispersity index (PDI) and zeta potential of the
AuNPs coated (or not) with three natural polymer layers are
presented in Table 1. The citrate-coated AuNPs present a
negative charge, which changes to positive with the adsorption
of chitosan (1st and 3rd layer). The adsorption of heparin (2nd
layer) to chitosan led to the appearance of NPs presenting an
electrical charge of the same signal (35.9  3.7 mV) for the
uncoated AuNPs. The size of the NPs increased, as expected,
with the adsorption of the polymer layers. Additionally, from
Table 1 it is also possible to conclude that the sequential
adsorption of the natural polymers leads to a more homoge-
neous population of NPs in terms of size (the PDI of the natural
polymers-coated AuNPs is lower than AuNPs).
AFM and TEM micrographs (Fig. 2) show that the produced
particles present a spherical shape. Moreover, TEM images
(Fig. 2A2) allow visualization of the polymeric coating around
the AuNPs. These techniques also permit the determination of
their size, which is not in agreement with the DLS data. Indeed,
the size of the natural polymer-coated AuNPs obtained by AFM
was between 25 and 35 nm, and the size obtained by TEM was
between 22 and 35 nm.
The size of the natural polymer-coated AuNPs was further
analysed by NTA. Besides the measurement of this physical
property, this method allowed the real-time visualization of
the particles (Video S1, ESI†) and the determination of their
concentration. The sizes of the natural polymer-coated AuNPs
obtained by this technique (Fig. 3) were in agreement with the
DLS data.
The positive surface charge of the NPs confirmed the
presence of chitosan in the last layer, which was also corroborated
by FTIR (Fig. 4). Finally, since chitosan has a greater number of
amino groups in the structure, which are not present in heparin,
their quantification (Table 2) also confirms that the last layer is
composed of chitosan.
3.3. Cellular assays
The morphology of chondrocyte cells cultured in the presence
of increasing concentrations of AuNPs or natural polymer-
coated AuNPs is presented in Fig. 5. The cells maintained their
morphology even after 72 h of contact with NPs. Additionally,
MTS assay results (Fig. 6) showed that chondrocyte cells
Fig. 1 QCM-D data for the build-up of the three layers. Frequency and
dissipation shifts recorded in real-time (A), and DD/Df plots for the
assembly of (Chit–Hep–Chit) using the 3rd overtone (B).
Table 1 Zeta potential, diameter and PDI values obtained by DLS and laser
Doppler electrophoresis, respectively, for AuNPs coated (or not) with three
layers of natural polymers, namely chitosan (Chit) heparin (Hep) and
chitosan (Chit)
NPs composition
Zeta potential
(mV) Size (nm) PDI
AuNPs 22.7  5.6 22.5  1.6 0.557  0.085
AuNPs + Chit +
Hep + Chit
+29.3  5.2 164.2  11.1 0.226  0.029
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remained viable throughout the experiment and no significant
diﬀerences, except the Au concentration of 160 mM in the
uncoated AuNPs at 48 h, were observed between the standard
culture conditions (0 mM of Au) and the NPs at diﬀerent
concentrations, for the diﬀerent time points. As expected,
the presence of natural polymers enhanced the ATDC5 cell
viability.
The cell proliferation assay (Fig. 7) clearly demonstrated that
the NPs presented significant inhibition of cell proliferation
only for concentrations above 80 mM (Kruskal–Wallis test,
Tukey’s HSD test, p o 0.01). Furthermore, suspensions of
AuNPs having a Au concentration of 10 and 20 mM generally
displayed a significantly higher cell proliferation than all other
concentrations of NPs (Kruskal–Wallis test, Tukey’s HSD test,
po 0.01), despite their coated counterparts. Chondrocyte cells
were also able to increasingly synthesize proteins throughout
Fig. 2 Representative TEM (A) or AFM (B) images of AuNPs without (1) or with three layers of natural polymers (2). The arrows (t) indicate the coating
surrounding the AuNPs.
Fig. 3 NTA analysis of the natural polymer-coated AuNPs size
distribution.
Fig. 4 FTIR spectra of chitosan (Chit), heparin (Hep) and AuNPs after
coating with two layers of Chit interspersed with one layer of Hep.
Table 2 Concentration of amino (NH2) groups in the presence of
increasing concentrations of natural polymer-coated AuNPs (measured
in terms of the Au atom concentration using ICP-OES)
[Au] (mg mL1) [NH2] (mM)
500 18.0  3.4
1000 55.2  12.9
2000 132.0  22.5
4000 272.2  24.4
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the experiment, although no significant differences were
observed between the standard culture conditions (i.e. cultured
in the absence of Au) and the NPs at different concentrations,
for the different time points (Fig. 8). Interestingly, and following
the trend of the viability results, the presence of natural polymers
induced ATDC5 cells to synthesize more protein than the AuNPs
concentrations of their counterparts.
3.4. AuNPs functionalization
The covalent coupling of the anti-bFGF antibody was deter-
mined by an indirect method, through the measurement of
the fluorescence of the unbound secondary antibody. The
diﬀerence between the fluorescence obtained for the total
amount of the secondary antibody used and that acquired in
the presence of diﬀerent concentrations of NPs allowed the
determination of the quantity that was retained by the particles
(Fig. 9). Considering the molecular weight of the secondary
antibody, it was possible to obtain its number of moles and
consequently, the quantity of the anti-bFGF antibody presented
at the NPs surface (Table S1, ESI†). Afterwards of removing the
unbound anti-bFGF antibody, equal amounts of bFGF were
added to diﬀerent concentrations of NPs suspensions. As can
be observed in Table 3, the functionalized AuNPs were able
to bind a higher percentage of bFGF; the suspension with
1000 mg mL1 of Au retained virtually almost all the GF added.
The size of the natural polymer-coated AuNPs with immo-
bilized anti-bFGF linked to bFGF was 176.6  12.5 nm, with a
PDI of 0.243  0.017 and a negative surface charge (26.6 
4.0 mV).
4. Discussion
This work aimed to develop functionalized AuNPs with the
potential for use in a theranostic approach related to the
regulation of diﬀerent cellular processes. Although immobi-
lized antibodies are usually used to direct NPs to a defined cell
or tissue, in the current study, they were used to specifically
bind a relevant bioactive factor. It was intended that the
captured agent would conduct the desired therapeutic eﬀect
after administration. To demonstrate the feasibility of the
developed AuNPs for used in a biomedical approach, NPs were
designed to immobilize a defined antibody that allows
the specific binding of bFGF, which has multiple biological
functions. However, instead of being incorporated into the
polymeric matrix, bFGF was linked to a specific antibody. Since
the anti-bFGF antibody used in this work is not a neutralizing
antibody, the GF can exert its key roles in a wide range of
biological functions.51
The construction of the LbL polymeric system was first
followed and analysed by QCM-D. The assemblies between
the positively charged chitosan and the negatively charged
heparin, using QCM-D equipment, have been the focus of
several studies in planar surfaces, and their multilayer con-
struction (up to 10 layers) is described in literature.69–71 Herein,
we focused on the analysis of the adsorption of three layers (two
layers of chitosan interspersed with one layer of heparin),
following its construction in real-time by monitoring the fre-
quency (Df) and dissipation (DD) shifts, for the 3rd, 5th and 7th
overtones. The adsorption of each layer involves three major
steps:72 (1) rapid adsorption of the polyelectrolyte; (2) poly-
electrolyte saturation onto the Au quartz crystal surface and
reorganization of the layers; (3) the washing step, in which the
loosely bound material is removed (Fig. 1A). The adsorption of
chitosan and/or heparin led to a change in the quartz sensor
oscillation, with its resonance frequency being lower. The shift
in resonance frequency is related to the mass adsorbed on the
quartz sensor, not only by the material itself, but also by the
coupled water. The energy dissipation changes represent
the viscoelastic properties of the layers, since the higher the DD,
Fig. 5 SEM micrographs (1000 magnification) of chondrocyte cells cultured in the absence (a) or in the presence of increasing concentrations of
AuNPs (b: 10 and c: 160 mM of Au atoms) or AuNPs covered with three polymeric layers (d: 10 and e: 160 mM of Au atoms), after 24, 48 and 72 h. The Au
concentration was determined by ICP-OES.
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the softer and/or more hydrated is the polymeric system; on the
other hand, the lower the DD, the more rigid and compact is the
film. Chitosan and heparin had opposite behaviours regarding
the frequency and dissipation signal changes (Fig. 1A). The
adsorption of chitosan (1st and 3rd layers) presented higher
frequency and dissipation shifts compared to heparin (2nd layer).
These higher values of frequency and dissipation suggest that the
mass of chitosan is sensed, as well as the water entrapped in its
structure, leading to an increase in Df and DD values.73 Therefore,
while the adsorption of the chitosan layers is accompanied by a
large dissipation shift, the heparin layer has a very small DD shift,
forming a less hydrated layer. To confirm the water content
hypothesis (observed on QCM-D signals), DD/Df was plotted as a
function of the deposited layer (Fig. 1B) in order to evaluate the
dissipation per adsorbed mass. This normalization of the dissipa-
tion by the adsorbed mass can better detail the hydration state of
the adsorbed layers. The higher values of the normalized dissipa-
tion (DD/Df) obtained by chitosan indicate that this polycation
produces more hydrated layers when compared with heparin.
In fact, heparin is a highly sulphated polyelectrolyte and because
Fig. 6 Box plots of cell viability when cultured in the absence (cells
cultured only with culture medium) or in the presence of increasing
concentrations (10, 20, 40, 80 and 160 mM of Au atoms determined by
ICP-OES) of AuNPs or AuNPs covered with three polymeric layers after 24,
48 and 72 h. Data were analysed non-parametrically using the Kruskal–
Wallis test, followed by Tukey’s HSD test. Statistically significant differences
are indicated as follows: a denotes significant differences compared to
160 mM of Au in AuNPs, b denotes significant differences compared to
10 mM of Au in AuNPs, c denotes significant differences compared to
20 mM of Au in AuNPs, and d denotes significant differences compared to
40 mM of Au in AuNPs.
Fig. 7 Box plots of ATDC5 cell proliferation in the absence (cells cultured
only with culture medium) or in contact with increasing concentrations
(10, 20, 40, 80 and 160 mM of Au atoms determined by ICP-OES) of AuNPs
or AuNPs covered with three polymeric layers after 24, 48 and 72 h. Data
were analysed by the non-parametric Kruskal–Wallis test, followed by
Tukey’s HSD test. Statistically significant differences are indicated as
follows: a denotes significant differences compared to 80 mM of Au in
AuNPs, b denotes significant differences compared to 20 mM of Au in
AuNPs, c denotes significant differences compared to 10 mM of Au
in AuNPs, d denotes significant differences compared to 40 mM of Au in
AuNPs, e denotes significant differences compared to 160 mM of Au
in AuNPs, f denotes significant differences compared to 10 mM of Au in
coated AuNPs, g denotes significant differences compared to 20 mM
of Au in coated AuNPs and h denotes significant differences compared
to 80 mM of Au in coated AuNPs.
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of the negative charge of SO3
, which is spread over three oxygens,
it is considered a weakly hydrated anion.74 It is important to note
that despite the film being considered as ‘‘quasi-rigid’’, the water
content, particularly on the chitosan layers, also contributes to the
thickness estimation. In this sense, the thicker chitosan layers
might be associated with the entrapment of water, leading to a
thicker coating. After the QCM-D analyses, the assembly of the
natural polymers was monitored by zetasizer measurements. The
change observed in the surface charge of the NPs constitutes
a good parameter to evaluate the adsorption of the polymers.
As chitosan was solubilized in 0.15 M NaCl (0.5 mg mL1, pH 5),
presenting a positive charge (+25.7 0.2 mV), it was expected that
its adsorption to the NPs surface would confer a positive charge.
The opposite was observed for heparin since it had a negative
charge (19.9  1.6 mV) when dissolved in 0.15 M NaCl
(1 mg mL1). The zeta-potential variation with the adsorption of
each polymer layer was accompanied by an increase in the NPs
size and homogeneity (lower PDI). However, the diameter of the
natural polymer-coated AuNPs obtained by DLS (Table 1) was
very different from that obtained by AFM and TEM (Fig. 2).
The differences observed between the DLS and the microscopic
techniques may be explained by the fact that in the first technique
the analysis was performed in an aqueous suspension and in the
other methodologies the samples were analysed in the dry state.
The data obtained by DLS are not directly comparable with AFM
and TEM results, nor with the data gathered by QCM-D measure-
ments. DLS provides an indication of the hydrodynamic diameter
of the particles by means of a sphere with the same translational
diffusion coefficient as the particles under study. This type of
analysis also assumes a hydration layer surrounding the particle
that is not accounted for in the QCM-D analysis, thus leading to
the differences in the thickness of each layer obtained by QCM-D
and DLS, qualitatively. However, the QCM-D and DLS data are
consistent, since the adsorption of chitosan led to thicker layers
than the ones obtained for heparin (data not shown).
NTA was used to further analyse the size of the natural
polymer-coated AuNPs. In this technique, the size was mea-
sured using the same principle of the Zetasizer equipment
Fig. 8 Box plots of total protein synthesis by ATDC5 cells cultured in the
absence (cells cultured only with culture medium) or in the presence of
increasing concentrations (10, 20, 40, 80 and 160 mM of Au atoms
determined by ICP-OES) of AuNPs or AuNPs covered with three polymeric
layers after 24, 48 and 72 h. Data were analysed by the non-parametric
Kruskal–Wallis test, followed by Tukey’s HSD test. Statistically significant
differences are indicated as follows: a denotes significant differences
compared to 20 mM of Au in AuNPs, b denotes significant differences
compared to 40 mM of Au in AuNPs, c denotes significant differences com-
pared to 160 mM of Au in AuNPs, d denotes significant differences
compared to 10 mM of Au in coated AuNPs and e denotes significant
differences compared to 40 mM of Au in coated AuNPs.
Fig. 9 Percentage (%) of the secondary antibody (2nd Ab) linked to the
anti-bFGF antibody immobilized at the surface of natural polymer-coated
NPs, in the presence of increasing concentrations of AuNPs. Au concen-
tration was determined by ICP-OES.
Table 3 Percentage of recombinant human bFGF bound to the antibody
immobilized at the natural polymer-coated AuNPs surface
[Au] (mg mL1) bFGF bound (%)
250 83.2  5.9
500 93.8  4.4
750 96.0  3.8
1000 99.6  0.3
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(light scattering) and it was not surprising that the data
acquired from both analyses were in agreement (Fig. 3 and
Table 1). Additionally, since NTA allows the real-time visualiza-
tion of the particles (Video S1, ESI†), it is possible to conclude
that the increase in NPs size was not due to their aggregation.
The NTA analyses clearly showed that the natural polymer-coated
AuNPs were spherical and were separate entities. Indeed, the
coating of the AuNPs with polymers can lead to a significant
increase in their size. Labala et al.,75 for example, reported that
the size of the AuNPs increased from 26.6  2.6 nm to 98.5 
4.3 nm after being coated with 3 layers of synthetic polymers.
Additionally, similar behaviour of the PDI values was observed,
since a more homogeneous population was obtained with an
increase in the number of layers. The observed increased in size
can be higher if natural polymers are used; synthetic polymers are
in general less hydratable than natural polymers. For instance, the
coating of silica NPs with poly-L-lysine and hyaluronic acid led to
an increase in their size to about 327 nm, with the natural
polymer contributing toE91% of that increment.76 Additionally,
it was demonstrated that coating AuNPs of size 24.0  6.2 nm
with glycol chitosan increased their diameter to 99.4  16.8 nm.77
A similar result was obtained by Bhumkar et al. using chitosan.78
As in NTA, it was necessary to dilute the NPs suspension to a high
degree, it was also possible to conclude that the electrostatic inter-
actions between the AuNPs and the natural polymers were strong
enough to avoid their decomplexation.79 Indeed, in ionically cross-
linked NPs, the electrostatic forces should promote the required
stability until NPs accomplished their biological activity.77,80–88
The biological assays, through the SEM images of the chondro-
cyte cells cultured in the presence of increasing concentrations of
AuNPs coated (or not) with natural polymers (Fig. 5), demonstrated
that NPs interact with cells without a negative eﬀect on their
density, shape and volume (without shrinkage). However, in
Fig. 5e, a light gray structure is observed (which was not observed
in the control and in the other samples with AuNPs), which could
be due to the presence of the natural polymer-coated AuNPs; it was
observed at higher magnification (the data are not shown) that the
light gray structure does not correspond to cells. Additionally,
the light gray structure is more visible in the first image (Fig. 5e),
most likely due to the presence of a smaller number of cells, a
shorter incubation time and a higher concentration of NPs, when
compared with Fig. 5d. Cells remained viable throughout the
experiment (Fig. 6). Furthermore, the ATDC5 cells presented a
higher viability when cultured in the presence of natural polymer-
coated AuNPs, which was expected since AuNPs are usually
covered with polymers to impart biocompatibility.16 A similar
trend was obtained for cellular proliferation and protein synthesis,
despite the statistical significance. This is in agreement with
previous studies that also showed that, for example, citrate-
capped AuNPs of 18 nm are not toxic to the K562 leukemia cell
line at Au concentrations up to 250 mM.89 Additionally, it was
demonstrated that AuNPs presenting three diﬀerent sizes (18, 35
and 65 nm) and coated or not with five diﬀerent polymers (PEG,
glucosamine, hydroxypropylamine, ethanediamine, and taurine)
neither induced cytotoxicity nor impaired the morphology of
primary human dermal microvascular endothelial cells until the
concentration of 250 mg mL1.90 Moreover, natural-polymer coated
AuNPs present lower toxicity than synthetic polymer-coated
AuNPs.88 Finally, AuNPs covered with chitosan did not present
significant cytotoxicity against mammalian somatic and tumoral
cells lines (an immortal human keratinocyte and human lung
adenocarcinoma epithelial cell lines) in the concentration range of
125 mM to 1.25 mM and 7.1 to 714.4 mM, respectively.91
The immobilization of the anti-bFGF antibody on the surface
of the natural polymer-coated AuNPs was performed using the
NPs amino groups available from the chitosan layer (heparin does
not contain this functional group) and EDC/NHS solution. The
presence of chitosan/amino groups in the last layer was confirmed
by the positive surface charge of the NPs by FTIR analyses (Fig. 4)
and by the Ellman’s reagent method (Table 2). The immobiliza-
tion of the antibody was followed by its linking to bFGF, which led
to an increase in NPs diameter of approximately 7% in relation to
NPs without functionalization. Considering the size of anti-bFGF
(155 amino acids; 17.5 kDa) and bFGF (154 amino acids; 17.2 kDa
with a radius of 1.45 nm),47 it was expected that the overall size of
NPs did not suﬀer a remarkable increase. The negative charge of
the final system is due to the fact that either the antibody or the
bFGF presents a negative zeta potential in water (for example,
12.46  4.4 mV for 0.0125 mg mL1 of anti-bFGF antibody and
21.8  1.68 mV for 0.167 mg mL1 of bFGF). In vitro studies
demonstrated that a low dose (3 ng mL1) of this protein has the
ability to stimulate the proliferation and expression of extra-
cellular matrix proteins and cytoskeletal constituents.54 Conse-
quently, Hankemeier et al. proposed its use in the engineering of
bioartificial tendons and ligaments. The bFGF concentration
reached in the developed NPs (until a maximum of 60.3 
24.5 ng mL1), without a negative eﬀect in cell behaviour,
demonstrates the potential application of this nanoplatform in
the medical area since the bFGF linked to the antibody retains its
biological activity.92 This is extremely important since this GF
should be administered in a carrier to enhance its half-life and to
allow the maintenance of its bioactivity.
Conclusions
From all the obtained results, we conclude that AuNPs coated
only with natural polymers were successfully produced and are
capable of immobilizing an antibody, which allows the specific
binding of bFGF. The natural polymer-coated AuNPs demonstrated
enhanced cytocompatibility compared to the AuNPs. Moreover,
they allowed chondrocyte cells to grow and proliferate throughout
the course of the experiment. The strategy and the devices devel-
oped in this work allow for their being tailored to the monitoring
and treatment of diﬀerent diseases, when eﬃciently functionalized
for the proposed objective. In this sense, the developed AuNPs are a
promising tool to use as nanotheranostic platforms for diﬀerent
conditions, boosting healing processes.
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